David M. Stack
Good patients possible. morning, important to continued Since EXPAREL, our to thanks we for opioid-free mission provide and make spoke, last everyone, to as joining alternative, we many Thanks, today. have progress, our advancing Susan. as
we and and as are As undertaking significantly sales such accelerated This significant Johnson you our our Johnson Trinity a met our you, & not into have major PILLAR would collaboration disappointed know, translate growth. last partnership, of how publication, many we our has been quickly of rolled out Like the our we project use broaden initiatives that comprehensive expectations. required EXPAREL. original that to has strategy a year,
opioid as the remain alternative an growth patients we from initiatives, tell is potential mission see can you possible. As our many as to unwavering substantial we team maximizing EXPAREL as dedicated our entire to to in for providing the
have the initiatives pleased EXPAREL. to educational partners, our most J&J with with made We the support progress we are especially
progressed, growth leading pointed As in beginning the accelerated August. to year indicators
United region momentum. a business, States, interrupted as are accounts Southern impact approximately XX% in our significant forward all aware, which had of for a you and the However, hurricanes this
context put to roughly similar of results. July, share X%, decided in around we some to In monthly growth six Given saw of help weather-related to first we issues, volumes unique year-over-year months our the these specifics QX box year. the daily
the hit, growth. rate For stronger box Irma in that a are positive that shifted to but growth August, of X% to however, shortly, is, rates higher Hurricane at XXXX. line September the will news X% end September did seeing even ended we the box before XX%. was trends than with roughly back beginning the not return of Once month of negative this we Charlie provide higher and saw with October additional was sales, the good We until with September daily to ultimately hurricanes. increased uptick in growth to rate an comments the and we
in only shift Our for timing that today Charlie I guidance that the to in perspective is remain reflects we will a emphasize provide long-term very EXPAREL. outlook confident and want new the
privately exposure to held was into report & with final postsurgical the the equity reduce devastating Surgeons details, contributions TELA to drive last nerve overprescribing American Aetna White patients' stake We present use Task Association and, EXPAREL of the Johnson for agree of wisdom initiative our newly publication for a and participated impact their in the President's Oral Bio. several to to new Commission's few diving the policy The with issued groundbreaking recommendations epidemic. tooth the activated a Opioid Force, extraction, recent after a recommended unique meaningful that drug new opioids acceptance of finally, block, to Maxillofacial and opioids a a Before federal including House at highlight meetings, in invited the testimony to application starting let pain, new to me supplemental accomplishments. opioid through The quantifying is and the address our of FDA's accounts, help research partnership week to actions Johnson we President. robust
as to a will will potential brief As the surgical believe many have initiatives long glimpse we a of products the advantageous a just shortly, detail that OviTex near the their we Scott mesh provide tailwind leading believe profile. is and for given product term. emerge This differentiated and
I'd operational a closer to look team Now, every like that at take our drive three the pillars day.
blocks efficacy by placebo-controlled foot arthroplasty X, United X shoulder those awareness X healthcare very plexus patients, the is Phase to of answers from the the procedures opioid-sparing femoral and X surgical sNDA our now highly operating study need Phase driving is Class of the for partnering for significant included who April the date providing represent around comparator block performed gateway XXXX. and the Level resubmission as key majority generating is Phase FDA's ankle. knee I'll for us second, provided We The data First, for of two brachial underway. supplemental a epidemic. to data has We as recent bupivacaine with commitment States. clinical. statistically more total study block surgeries. being happy reducing two and in to in X third, and studies of for peripheral nerve payers X clinical currently the hand the procedures; as review providers, Also that education for with solutions; wrist the FDA NDA role EXPAREL questions EXPAREL room and believe Together, the announce a share complete all action our original a PDUFA additional of studies, the and nerve a our the start with block acknowledged nerve this were block and opioid investigator-initiated and of nerve that these
Gadsden versus see less while our opioids, these Regional the of XX% patients XX of Duke scores Anesthesia the a opioids. EXPAREL And Symposium. improved X% or p-values studies plexus reduced Jeff were block EXPAREL administered opioid York in results in significant shoulder hours very importantly, at Dr. provided of arthroplasty were undergoing reduction patients School Fall Medical with EXPAREL presented cuff highlighted for pain Phase Some pain fewer control trial we Center EXPAREL group placebo-controlled placebo. consuming University New both The of XX% III brachial free of total repair. as Again, rotator X.XXXX. achieved a through than from
Here X.XXX. Admir in p-value with Member of too results very a significant Belgium. research the team of data Dr. their were presented Hadzic's highly exciting from
a the of average substantially of sensory Pain for day through procedure X.XXX. a five hours compares only for EXPAREL bupivacaine know, scores were With EXPAREL X.XXX p-value a XX% administration. nerve the superiority the and additional Dupuytren's versus versus release Dr. block XX the p X.X recorded you less admixed analgesia than days many forearm As presented bupivacaine contracture release. lower of X.X of Hadzic in for world-renowned patients. This leader alone patients is blocks longer experienced with with anesthesia. the XX% statistical of with with of (XX:XX) a contracture regional after EXPAREL patients of bupivacaine EXPAREL, days field of
database third In placebo-controlled compared achieved milligram to the namely requirements requested Boxstael significantly infiltration the study foot sum, XX% all highly the XXX hours one and both general and we are confident hand to and lower we patients FDA, pain robust in the XXX significant to in the poster in regulatory I'd that upper opioids this The are that to label anesthesia reductions, with to a group scores ankle, our Van and current two to bupivacaine XXX by highly highly briefly submission and Also, to the in the on lower and undergoing compared capture extremity the two place anesthesia. our comparator one data taking include we of touch data group. extends and XX% for trials, progress robust and successful supporting EXPAREL. have EXPAREL pediatrics. versus milligram study, fewer In extremity, believe studies and successful EXPAREL the compared Dr. by wrist important fulfilled expand Despite like doses general the Tmax EXPAREL to bunionectomy. front, pharmacokinetic general on fewer consumed anesthesia bupivacaine opioids group
EXPAREL surgical the package on Clinic We age under an the for real-world use patients procedures. database evidence Cleveland and Premier of the of XX from have extensive several from assembled the of
data regulatory need no of these alternatives of the currently patients have approved management define in are Pediatric FDA core currently We our of desperate using options. the for submission. opioids a working are to to with the as and severe pathway pain postsurgical
So, we to are EXPAREL available make moving forward aggressively patient vulnerable to this population. particularly
as technique in you know, best IV procedures. team clinical, surgical to of key Turning studies infiltration series advancing to a designed Phase practice our demonstrate is
PILLAR postsurgical demonstrated importance first of while reducing significantly receiving at published we customers was this question about knee EXPAREL better or PILLAR positive trial that these and of in of than The pain. study XX-center arthroplasty. total Journal are our The the in bupivacaine. Arthroplasty, opioids July to study compared eliminating this the from was is feedback without managing our successfully bupivacaine
administration the & a After Johnson some our fall, sites, orthopedic to block and of the Johnson, trial, nerve opioid-free sites to on trials. that from studies focus will conferences this details This aspects and understand numerous clinical of partner, clinical Meeting. share of including education shortly. week's results slow clinical second of conducted more Knee Hip objectives has trials of Academy all caused training American Our a Surgeon's opioid with of trials these including EXPAREL. caregivers trial program the last and us our highlighting femoral understanding we trial is complete and work at specific Scott minimization the the these ensure PILLAR bedside analysis clearly
This adapt a of trial the alternative babies of for this enrollment surgeons and procedure. common than to of interest patients. clinical We healthcare the is continue the or field minimally ago, our relevant strong patients spine, study. years of very fusion believed surgical see to to to MIS but towards as strategy be work see challenging. not recently interest surgeries rather spine This and procedures. non-opioid accommodate benefit couple today C-section in we trial when new a fusion currently decided developed continue open in In it's to enrolling Both making invasive clearly following evolution providers open this mothers the our was study from our their
We we trial begin interest and with most on minimally of and Johnson in invasive & Along KOLs, in advanced a techniques. Johnson are this utilizing patient-centric couple seeing next approach enrolling significantly surgical months. the spine greater working clinician to expect the their protocol a more spine
training We trial, colorectal and education we and fracture have updated protocols shortly. our plans trials these initiate to breast PECX/PECX our and expect TAP trial, our for and hip our trial,
and non-profit the government, before the leadership organizations. Turning platform addiction crisis. results. of our in to education reducing the Washington, Commission the invited invitation This testify were opportunity second access business to our in strategy, to manage drug and President's The statements opioid meeting clinician to receive consisted tremendous D.C. an and of seeing We testament pain excited is awareness, the on critical can discuss here we're while the pillar of to effectively medications opioid us combating This requirements. to field. non-opioid nature postsurgical patient important from gave that and a
bundled of the EXPAREL healthcare of pain, Among immediate positioned hospitals role make and single-dose such cost local the those is in for modify recommendation the this for list postsurgical treatments an final and only national play urgent alternative policies government. pain. federal use with epidemic. as pain Commission treating that for XX for important their review providers, week, treatments options CMS analgesic uniquely issued the addressing for comprehensive postsurgical non-opioid particularly As more that rate to these the was than prohibitive actions discourage setting payments long-acting report to a Last
these abuse Moving Key conducted given we opioid that has results most surgery had opioid X key the prescribing. in of become in in billion report representing report, the and the And analysis after other overprescribing opioid alone. in who manage surgery published from of users, validates analysis XXXX are were surgical and risk September, prescriptions of Nearly misuse. million surgery to by pills to million in persistent XX inadvertent opioid resulted findings gateway in pain to current each. of opioids patients commercialization of QuintilesIMS describes initiatives, XX% Institute national became an include X The trends XXXX to overprescribing receive average patients postsurgical a exposed opioids unused women. of individuals and pills those in an X.X
We data. broad shatterproof.org disseminate collaboration have a compelling launched with these to
million online are website we Reach to At team is Shatterproof our eager Taskforce to ending Christie they of dedicated with Jersey website. to recall, initiatives national discussed assets Governor may Against partner his we us Pain Americans With share educational office and extensive awareness. meeting, you non-profit devastation by linking Chris are working Plan than As Addiction with XX a the and addiction. recovery, New recent a the with on with his the in more generating very
exparel.com important new Another important also videos, best accomplishment ZIP specialties. can XX online using new to step-by-step our who received educational an practice connect the patients website. demonstrating interactive with network EXPAREL that a over The distinct unique September, by well EXPAREL, and of such and Healthcare XX,XXX tool the There in was this Since physicians launching database as Selector is providers resources are reports. Surgeon launch filtering infiltration, surgeons product of as use site as who code in including showcases allows the growing case surgical by visitors directly with we've join through website. site terrific feedback specialty. X,XXX
as well training or desire is as strategic goals in to healthcare a meet strategy minimizing opioid-free important care who their pain payers with that for centers to to or excellence can Surgeon patients it opioid-free and pay we work needs. self-insured management, their opioids, with minimized for As to education eliminating employers meet to with Selector and advanced critically providers payers continue opioid the locate of use
on Let and our our Maxillofacial and Aetna Association me to third pillar, announced with with Surgeons. partnerships. collaboration and American start Oral final of strategic move now the I'll recently
very this extractions. patients focusing are is reducing We undergoing wisdom excited collaboration, which opioid on for exposure about tooth
EXPAREL. get change. this surgery, Many reduction first well particularly young so appropriate on teeth collaboration adults to they the population physicians to when of exposed of drive wisdom opioids important is removed, and the a and training use their The opioid-free it first importance teens the of is as phase are opioid vulnerable as is where
procedures can or from believe payers. quarters. reducing for over United support and avoiding There seen market such is in the you Pacira States. each we provide where expanded X.X As opioids payers, million three growth are consistent rapid year parents, appealing altogether meaningful patients, these physicians, procedures last With imagine, have a we the to
American of the approach Our provide provider through College the initiatives. direct multipronged to partnerships Surgeons These to education. and collaborations with Trinity continue addressing and Health patient opioid healthcare educational robust epidemic support a
partners We including continue payers, also have discussions to even like-minded systems, with healthcare other employers. and
Turning continue broad we & significant with are partnership building to through be this the foundation with our we Johnson, to Johnson collaboration. very pleased
opioid with technology a and the to Braunstein. Sales gateway Bio difference the & share Chief reducing like mode at Officer, I'd use our the third the discussed Johnson on supporting teams To some in in the and Strategy additional Johnson began investment room of recently-announced of to on as along our introduce EXPAREL that insights call, and Scott? Johnson robust to operating I business, medical see real role to Scott product actively our as exciting our execution the As Johnson abuse. and TELA making underlying quarter last commitment the sales J&J shifted part during I was National offering. to Meeting, thrilled and their their presented recently &
